US Broker Ratings

Owens & Minor, Inc. (OMI) Stock Analysis: Exploring the 94% Potential Upside in Healthcare Distribution

Owens & Minor, Inc. (OMI), a key player in the healthcare sector, specifically in medical distribution, presents an intriguing opportunity for investors. Despite facing challenges, the stock currently trades at..

Cogent Biosciences, Inc. (COGT): Investor Outlook on a Biotech Innovator with a 28% Upside Potential

For investors with a keen eye on the biotechnology sector, Cogent Biosciences, Inc. (NASDAQ: COGT) presents an intriguing opportunity marked by significant growth potential. Headquartered in Waltham, Massachusetts, Cogent Biosciences..

Neuropace, Inc. (NPCE) Stock Analysis: Exploring a 10.95% Potential Upside with Strong Buy Ratings

Investors with a keen eye on the healthcare sector, specifically in the realm of medical devices, may find Neuropace, Inc. (NASDAQ: NPCE) a compelling opportunity. With a market capitalization of..

Akebia Therapeutics, Inc. (AKBA) Stock Analysis: Unveiling a Remarkable 302.99% Potential Upside

Akebia Therapeutics, Inc. (NASDAQ: AKBA) has captured the attention of investors with its notable potential upside of 302.99%. This biopharmaceutical company, focused on kidney disease therapeutics, offers a compelling investment..

Praxis Precision Medicines, Inc (PRAX) Stock Analysis: Navigating the 55% Potential Upside in Biotech

Praxis Precision Medicines, Inc (NASDAQ: PRAX) is capturing investor attention with its promise of substantial growth in the biotechnology sector. With a focus on central nervous system (CNS) disorders, this..

Pharvaris N.V. (PHVS) Stock Analysis: A 78.62% Potential Upside and Strong Buy Ratings

For investors with a keen interest in biotechnology, Pharvaris N.V. (PHVS) presents a compelling opportunity with strong growth potential. Listed in the healthcare sector under the biotechnology industry, this Swiss-based..

Immatics N.V. (IMTX) Stock Analysis: A Deep Dive into its 92.79% Potential Upside

Investors interested in the biotechnology sector should turn their attention to Immatics N.V. (NASDAQ: IMTX), a clinical-stage biopharmaceutical company specializing in cutting-edge cancer immunotherapies. Headquartered in Tübingen, Germany, Immatics is..

Avadel Pharmaceuticals (AVDL) Investor Outlook: Navigating a 54.90% Revenue Growth Amidst a Hold-Heavy Consensus

Avadel Pharmaceuticals plc (NASDAQ: AVDL), a biopharmaceutical company based in Dublin, Ireland, is carving out a niche in the healthcare sector, specifically within the drug manufacturing arena for specialty and..

Bicycle Therapeutics plc (BCYC) Stock Analysis: Unpacking a 232% Potential Upside

Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company based in Cambridge, UK, is drawing significant attention in the healthcare sector. With a market capitalization of $448.81 million, the company is..

Zymeworks Inc. (ZYME): Analyzing the 50% Upside Potential in Biotech Innovator

Zymeworks Inc. (NASDAQ: ZYME) is making waves in the biotech sector with a notable potential upside of 50.72%, attracting significant interest from investors seeking opportunities in healthcare innovation. With a..

iRadimed Corporation (IRMD) Stock Analysis: Navigating Healthcare’s Pinnacle with a 23.31% ROE

iRadimed Corporation (NASDAQ: IRMD), a standout player in the healthcare sector’s medical devices industry, is capturing attention with its impressive financial metrics and strategic positioning. Headquartered in Winter Springs, Florida,..

Day One Biopharmaceuticals, Inc (DAWN) Stock Analysis: High Potential Upside with a 124% Growth Prospect

Day One Biopharmaceuticals, Inc. (NASDAQ: DAWN), a commercial-stage biotechnology company, is garnering attention with its ambitious focus on developing treatments for both childhood and adult diseases. With a market capitalization..

Arcus Biosciences, Inc. (RCUS): Analyst Consensus Reveals a 51.45% Potential Upside for Biotech Investors

Arcus Biosciences, Inc. (RCUS), a clinical-stage biopharmaceutical company based in Hayward, California, is making waves in the biotechnology sector with its innovative cancer therapies. With a market capitalization of approximately..

Trevi Therapeutics, Inc. (TRVI) Stock Analysis: Exploring a Nearly 98% Upside Potential

Trevi Therapeutics, Inc. (NASDAQ: TRVI) is capturing investor attention in the biotechnology sector due to its compelling growth prospects and a substantial upside potential. As a clinical-stage biopharmaceutical player, Trevi..

Vir Biotechnology, Inc. (VIR) Stock Analysis: Potential 175.99% Upside and Strong Buy Ratings Signal Investor Opportunity

Vir Biotechnology, Inc. (NASDAQ: VIR), a clinical-stage biopharmaceutical company, is catching investor attention with its promising 175.99% potential upside and unanimous buy ratings. With a focus on developing therapies for..

HealthStream, Inc. (HSTM) Stock Analysis: Exploring a 47% Potential Upside with Robust SaaS Solutions

HealthStream, Inc. (NASDAQ: HSTM), a prominent player in the health information services sector, offers a compelling investment narrative for those interested in the burgeoning intersection of healthcare and technology. With..

Replimune Group, Inc. (REPL) Stock Analysis: Unveiling a 72% Upside Potential in Oncolytic Immunotherapy

Replimune Group, Inc. (NASDAQ: REPL) has carved a niche for itself in the burgeoning field of oncolytic immunotherapy, offering promising prospects for investors willing to engage with the dynamic and..

Anavex Life Sciences Corp. (AVXL) Investor Outlook: Unpacking a Potential 353.61% Upside

Anavex Life Sciences Corp. (NASDAQ: AVXL) is a name that continues to capture the attention of the biotechnology sector, especially among investors seeking substantial growth potential. With a market cap..

Fulgent Genetics, Inc. (FLGT) Stock Analysis: Unlocking a 17.51% Potential Upside in Healthcare Diagnostics

Fulgent Genetics, Inc. (FLGT) is making waves in the healthcare sector, particularly within the diagnostics and research industry. Based in El Monte, California, this innovative company offers a comprehensive suite..

AnaptysBio, Inc. (ANAB) Stock Analysis: Promising Upside Potential with 42.52% Growth Outlook

AnaptysBio, Inc. (NASDAQ: ANAB), a clinical-stage biotechnology firm specializing in immunology therapeutics, is capturing the attention of investors with its remarkable upside potential. With a market capitalization of $1.3 billion,..

US Broker Ratings

US Broker Ratings

FTSE 100

Funds